Collagen Diseases  >>  Palexia RP (tapentadol extended release)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
NCT00361504: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Completed
3
1123
US, Canada
Oxycodone CR, Tapentadol (CG5503) ER, CG5503
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH
Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
07/08
07/08
NCT00487435: An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Completed
3
1166
US, Canada, RoW
Tapentadol (CG5503) Extended Release (ER)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH
Pain, Osteoarthritis, Low Back Pain
06/09
06/09
NCT00784277: A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Completed
3
597
US
oxycodone CR, oxycodone IR, Tapentadol ER (CG5503), Tapentadol IR (CG5503), placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Grünenthal GmbH
Joint Diseases, Arthritis, Osteoarthritis
07/09
07/09

Download Options